Clinical trial
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
NCT00034281 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00034281 |
|---|---|
| Title | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 |
| Official title | A Phase I, Open-Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose and Pharmacokinetics of Oral TAK-165 Administered Once Daily to Subjects With Tumors Known to Express HER2. |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm |
| Intervention type | Drug |
| Interventions | TAK-165 |
| Enrollment | 16 |
| Start date | Jun 1, 2002 |
| Primary completion | Sep 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | Apr 25, 2002 |
| Last update posted | Feb 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: